Ativa Medical is a technology company.
Ativa Medical has raised $15.0M across 1 funding round.
Ativa Medical has raised $15.0M in total across 1 funding round.
Ativa Medical is a privately held medical technology company founded in 2008 and based in St. Paul, Minnesota, specializing in point-of-care diagnostic devices.[1][2] It develops the Ativa Micro Lab, a compact tabletop system the size of the original iMac that performs critical hematology and blood chemistry tests—such as complete blood counts—using just a few drops of blood on inexpensive disposable microfluidic cards, delivering results in 5 minutes.[1][5] The platform serves healthcare professionals in clinical settings like clinics, enabling on-site testing for diseases including sepsis, and addresses delays in traditional lab processing by combining flow cytometry, electrochemistry, colorimetric testing, and imaging technologies protected by multiple patents.[1][2]
The company has raised $28.27M in funding, with its last round of $250K five years ago, and remains in the "Loan | Alive" stage while pursuing commercialization.[2] Its growth momentum includes breakthroughs like recent complete blood count test achievements, positioning it to enhance treatment decisions at the point of care and improve patient experiences through real-time results.[1]
Ativa Medical was founded in 2008 in St. Paul, Minnesota, by a team including co-founder and Chief Operating Officer Barbara Roth and co-founder and Chief Technology Officer David Deetz, PhD.[2][5] The idea emerged from expertise in miniaturizing complex lab processes, with Deetz noting the team's track record in tackling challenges where prior startups failed, focusing on hydrodynamic focusing to align and accelerate blood cells for accurate analysis.[2][5]
Early traction built around the Ativa Micro Lab platform, designed for CLIA-waived tests like hematology and chemistry using low-cost disposable cards estimated at $8 per test.[2][5] Key milestones include naming James M. McNally, PhD, as President and CEO, and ongoing development amid post-Theranos scrutiny, with the company emphasizing patented fluid processing to replicate core lab results at point-of-care.[4][5] Matt Mesnik, MD, as medical director, highlighted its clinical value for immediate patient discussions.[1]
Ativa Medical rides the point-of-care diagnostics trend, accelerated by demands for faster, decentralized testing post-COVID and amid chronic lab backlogs.[1][5] Its timing aligns with a shift toward affordable, portable devices that democratize access to hematology and chemistry panels, critical for sepsis and other acute conditions, countering reliance on expensive central labs.[2]
Market forces favoring Ativa include rising healthcare efficiency pressures, clinician needs for immediate results, and growth in CLIA-waived tech, though it navigates post-Theranos skepticism by focusing on validated, multi-patented methods.[5] The company influences the ecosystem by enabling on-site testing in clinics, potentially reducing costs and improving outcomes, while competing with firms like Hx Diagnostics in infectious disease rapid tests.[2]
Ativa Medical's path forward hinges on FDA clearance and commercialization of its Micro Lab, potentially scaling to wider CLIA-waived panels amid surging point-of-care demand.[1][5] Trends like AI-enhanced diagnostics and global health access will shape its trajectory, with its $28M funding base supporting expansion despite a quiet recent raise.[2]
Its influence could grow by transforming clinic workflows, fostering real-time care similar to its sepsis focus, and proving resilient post-Theranos—positioning it as a credible innovator in efficient, patient-centered diagnostics that began with a 2008 vision for miniaturized lab power.[1][2][5]
Ativa Medical has raised $15.0M in total across 1 funding round.
Ativa Medical's investors include Ping An Ventures.
Ativa Medical has raised $15.0M across 1 funding round. Most recently, it raised $15.0M Series B in September 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2015 | $15.0M Series B | Ping An Ventures |